DOCSLIB.ORG

Ethical Issues in Newborn Sequencing Research: the Case Study of Babyseq Lainie Friedman Ross, MD, Phd,A Ellen Wright Clayton, MD, Jdb

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Ethical Issues in Newborn Sequencing Research: the Case Study of Babyseq Lainie Friedman Ross, MD, Phd,A Ellen Wright Clayton, MD, Jdb Ethical Issues in Newborn Sequencing Research: The Case Study of BabySeq Lainie Friedman Ross, MD, PhD,a Ellen Wright Clayton, MD, JDb The BabySeq Project is a study funded by the National Institutes of Health and abstract aimed at exploring the medical, behavioral, and economic impacts of integrating genomic sequencing into the care of both healthy newborns and newborns who are sick. Infants were randomly assigned to receive standard of care or standard of care plus sequencing. The protocol and consent specified that only childhood-onset conditions would be returned. When 1 child was found to carry a BRCA2 mutation despite a negative family history, the research team experienced moral distress about nondisclosure and sought institutional review board permission to disclose. The protocol was then aMacLean Center for Clinical Medical Ethics and modified to require participants to agree to receive results for adult-onset- Departments of Pediatrics, Medicine, and Surgery, The b only conditions as a precondition to study enrollment. The BabySeq team University of Chicago, Chicago, Illinois; and Department of Pediatrics, Center for Biomedical Ethics and Society, asserted that their new protocol was in the child’s best interest because Vanderbilt University Medical Center, Nashville, Tennessee ’ fi having one s parents alive and well provides both an individual child bene t Dr Ross conceptualized and designed the and a “family benefit.” We begin with a short description of BabySeq and the manuscript, drafted the initial manuscript, and controversy regarding predictive genetic testing of children for adult-onset revised the manuscript; Dr Clayton conceptualized conditions. We then examine the ethical problems with (1) the revised and designed the manuscript and made critical revisions on multiple versions; and both authors BabySeq protocol and (2) the concept of family benefit as a justification for approved the final manuscript as submitted and the return of adult-onset-only conditions. We reject family benefit as a moral agree to be accountable for all aspects of the work. reason to expand genomic sequencing of children beyond conditions that DOI: https://doi.org/10.1542/peds.2019-1031 present in childhood. We also argue that researchers should design their Accepted for publication Aug 5, 2019 pediatric studies to avoid, when possible, identifying adult-onset-only genetic Address correspondence to Lainie Friedman Ross, variants and that parents should not be offered the return of this information MD, PhD, Department of Pediatrics, University of if discovered unless relevant for the child’s current or imminent health. Chicago, 5841 S Maryland Ave, MC 6082, Chicago, IL 60637. E-mail: [email protected] PEDIATRICS (ISSN Numbers: Print, 0031-4005; Online, 1098-4275). In 2014, the Eunice Kennedy Shriver impacts of integrating genomic Copyright © 2019 by the American Academy of National Institute of Children Health sequencing into the care of study Pediatrics and Human Development and the families of both healthy and sick FINANCIAL DISCLOSURE: The authors have indicated they have no financial relationships relevant to this National Human Genome Research newborns”2,3 via a randomized clinical article to disclose. Institute funded a consortium of 4 trial in which half of participants were FUNDING: Dr Clayton received support from 5U01 grantees to study newborn sequencing randomly assigned to receive standard HG008672-04 and 5RM 1HG009034-02. Funded by the in genomic medicine and public of care (family history and standard National Institutes of Health (NIH). 1 health. One of the awarded projects newborn screening) and half were POTENTIAL CONFLICT OF INTEREST: The authors have was entitled The BabySeq Project randomly assigned to have standard of indicated they have no potential conflicts of interest (Genome Sequence-Based Screening for care plus genomic sequencing. For to disclose. Childhood Risk and Newborn Illness), those in the sequencing arm, a newborn COMPANION PAPER: A companion to this article can a collaboration between Brigham and genomic screening report was be found online at www.pediatrics.org/cgi/doi/10. Women’s Hospital, Boston Children’s generated, “which lists pathogenic or 1542/peds.2019-3111. Hospital and the Broad Institute at likely pathogenic variants in genes that Harvard University, and Baylor College have been strongly linked to childhood- To cite: Ross LF and Clayton EW. Ethical Issues in of Medicine. Its aim was “to explore the onset diseases or diseases for which Newborn Sequencing Research: The Case Study of BabySeq. Pediatrics. 2019;144(6):e20191031 medical, behavioral, and economic intervention is possible during Downloaded from www.aappublications.org/news by guest on September 25, 2021 PEDIATRICS Volume 144, number 6, December 2019:e20191031 SPECIAL ARTICLE childhood.”2 For newborns with did the authors detail the perceived the child’s autonomy to decide as an a specific clinical presentation that benefit from the discovery. adult whether to undergo testing. potentially had a genetic etiology, an indication-based analysis was Because of their moral distress, the Sequencing raises the possibility of performed.2 researchers proposed to modify their discovering genetic information protocol to offer the optional return unrelated to the clinical question, The study researchers sought to of adult-onset-only genetic variants if known as “incidental” or “secondary” enroll 200 newborns and their both parents agreed. In response to findings. Although the American parents into each cohort (healthy the IRB’s concern that some parents College of Medical Genetics and infants and infants admitted to the might still not receive results under Genomics (ACMG) issued a statement “ NICU), but despite 22 months of the revised protocol, the researchers in 2012 that patients should be given recruitment and approaching 3860 modified the amendment to require the option of not receiving certain or fi ”15 families, they were only able to participants to receive results for secondary ndings, new recruit 268 infants (6.9%), 45 of 436 adult-onset-only conditions as recommendations in 2013 mandated “ (10.3%) from the NICU and 223 of a precondition to participate in the that laboratories performing clinical 5 3424 (6.5%) from the well-baby study. They explained that this sequencing seek and report … nursery.3 Overall, 159 infants were “avoids the ethical dilemma of mutations in all subjects, …”16 sequenced, 127 healthy infants and laboratory personnel knowing irrespective of age , a form of 32 infants in the NICU.4 something that is widely considered opportunistic screening, despite to be actionable but cannot be acknowledging that there are In January 2019, Holm et al5 reported returned.”5 They asserted that their “insufficient data on penetrance and that a male infant enrolled from the new protocol was in the child’s best clinical utility to fully support these 17 cardiac ICU at Boston Children’s interest because “the best interest of recommendations.” The original list Hospital was identified with a BRCA2 the child includes not only the child’s included 57 genes, which was quickly mutation despite a negative family future autonomy to make a decision revised to 56 genes, and has now history. The team wanted to return about what the child wants to know been increased to 59 genes (ACMG 17 these results despite the facts that (1) about him- or herself, but also having 59). the consent form clearly stated that his or her parents alive and well,”5 Many ACMG members objected to only childhood-onset conditions which they describe as “family – these recommendations.18 23 In would be returned,(2) the benefit.” After a brief description of response to the criticism that the new institutional review board (IRB) had the debate regarding predictive recommendations contradicted approved the study knowing that only genetic testing of children for adult- earlier policies about predictive childhood-onset conditions would be onset-only conditions in the clinical genetic testing of children, the ACMG returned, and (3) the study had and research settings, we examine (1) responded that the earlier policies obtained a US Food and Drug the ethical challenges raised by the were focused on children with “a Administration nonsignificant risk revised BabySeq protocol and (2) the known family history of risk, with the determination on the basis of the plan ethical problems with the concept of expectation that the child will be to return only the results of family benefit. offered testing at an age when he or conditions that could manifest in she can make an informed decision childhood.5 The team went back to about testing,”24 whereas the IRB and obtained permission to BACKGROUND: PREDICTIVE GENETIC opportunistic screening applied to recontact the infant’s parents to offer TESTING OF CHILDREN FOR ADULT-ONSET-ONLY CONDITIONS unsuspecting families for whom the the return of adult-onset-only information may benefit the child and fi ndings. The parents consented and There is a consensus within the parents. However, in April 2014, in were told the results. Although either pediatric, genetics, and ethics response to additional stakeholder parent could have been the BRCA2 communities, in the Unites States and feedback,25 the ACMG modified its fi carrier, when the ndings were globally, that children should not be clinical recommendation to allow shared, the mother recalled some tested for adult-onset-only 6–14 patients (and parents) to opt out of distant paternal relatives with breast conditions. The arguments to opportunistic screening and the and/or ovarian cancer, and she was support this position are as follows: return of the ACMG 59 results.26 referred to a familial cancer genetic (1) the information is not clinically risk clinic. The authors did not detail relevant to the child, and so testing is The ACMG guidelines were focused whether she went to the familial “not medically indicated” and could on the clinical setting, whereas cancer genetic risk clinic or whether create anxiety without any potential BabySeq is a research protocol.
Load more

Recommended publications
  • FALL 2004 DEAN Alex M
    FALL 2004 DEAN Alex M. Johnson, Jr. EDITORS Terri Mische Elizabeth Washburn CONTRIBUTING WRITERS Jana Bruder Cheryl Casey Amber Fox Susan Gainen Matt Gehring Ann Hagen Katherine Hedin Joel Hoekstra FALL 2004 Kay Johnson Contents Steve Marchese Meleah Maynard Pat McGroarty 1 THE DEAN’S PERSPECTIVE Todd Melby Laurie Newbauer Ruth L. Okediji 2 FACULTY FOCUS Mickelene G.Taylor Mary Thacker Faculty Research & Development Suzanne Thorpe Al Vredeveld 19 FACULTY ESSAY PHOTOGRAPHERS Bobak Ha’Eri Copyright and the Court Dan Kieffer Ruth L. Okediji Terri Mische Tim Rummelhoff Kevin Washburn 24 FEATURES DESIGNER Jennifer Kaplan, Achieving Excellence Red Lime, LLC Meleah Maynard The Law Alumni News magazine is published twice a year, by the The Faegre and Benson Symposium University of Minnesota Law School Office of External Law, Information, and Freedom Relations.The magazine is one of the projects funded through the of Expression membership dues of the Law Alumni Association. Correspondence should be to: 38 LAW SCHOOL NEWS [email protected] or Law Judge Doty Gives Keynote Address at Alumni News Editor, N160 Mondale Hall, 229 19th Avenue Minnesota Law Review Banquet South, Minneapolis, MN 55455-0400. Weekend Indian Law Course The University of Minnesota is Student Highlights committed to the policy that all persons shall have equal access to its programs, facilities and employ- ment without regard to race, col- 47 ALUMNI COMMONS or, creed, religion, national origin, sex, age, marital status, disability, Distinguished Alumni public assistance status, veteran Class Notes status or sexual orientation. In Memoriam Dean’s Perspective s I visit our alumni at various law firms, both in and out of state, I endeavor to provide them with current information regarding the Law School.
    [Show full text]
  • Joint Degree Program Consortium on Law and Values
    Annual Report 2004-2005 Joint Degree Program in Law, Health, & the Life Sciences™ Consortium on Law and Values in Health, Environment & the Life Sciences™ Highlights from 2004–2005: • 1st volume of Minnesota • 11 intramural Journal of Law, Science grants awarded & Technology published • New Associate Director • Success on NIH grant of Research & proposal on Education appointed research ethics • 24 JDP applicants • 2 new Consortium & 5 new JDP enrollees members • 1 new JDP graduate • Lecture Series on the • Publication from stem cell debate intellectual property • Lunch Series on medical symposium in MJLST devices & innovation • Publication from • Deinard Memorial conference on racial Lecture on genetics & ethnic categories in Nature Genetics • Conference on racial & ethnic categories • Publication from in biomedical research bioethics conference in Hastings Center Report • Open-submission symposium on the • New Visiting Consortium future of law & science Professorship • Cosponsorship of bioethics conference 2004–2005 Events Tuesday, November 2, 2004 Tuesday, April 5, 2005 Lunch Series on the Societal Implications Lunch Series on the Societal Implications of the Life Sciences of the Life Sciences Prof. Michael Lysaght, Brown University Alan Milstein, Esq., Sherman, Silverstein, “Risk, Reason & Regulation of Medical Kohl, Rose & Podolsky Devices” “Human Subjects Protection: A Plaintiff’s Perspective” Wednesday, December 8, 2004 Lecture Series on Law, Health Monday, April 18, 2005 & the Life Sciences Annual Conference Prof. Evan Snyder, Burnham Institute “Proposals for the Responsible Use of and University of California, San Diego Racial & Ethnic Categories in Biomedical “Stem Cell Biology: Good Ethics Depend Research: Where Do We Go From Here?” on Good Facts” Commentators: Profs. Paul Tuite, Jeffrey Kahn, Wednesday, April 20, 2005 University of Minnesota Lecture Series on Law, Health & the Life Sciences Wednesday, February 2, 2005 Prof.
    [Show full text]
  • University of Florida • Spessard L. Holland Law Center P.O
    BARBARA J. EVANS University of Florida • Spessard L. Holland Law Center P.O. Box 117620 • Gainesville, FL 32611-7620 (352) 273-0915 (office) • (713) 446-7576 (cell) [email protected] or [email protected] LEGAL EDUCATION J.D., Yale Law School, 1994 LL.M. Health Law, University of Houston, 2003 Admitted to practice: New York (since 1996), Texas (since 2000) OTHER EDUCATION Post-doctoral Fellow, Clinical Ethics, M.D. Anderson Cancer Center, 2003 – 2004 Ph.D., Earth Sciences, Stanford University, 1984 M.S., Applied Earth Sciences, Stanford University, 1982 B.S., Electrical Engineering, with Honors, University of Texas at Austin, 1979 CURRENT EMPLOYMENT University of Florida, Gainesville, FL (2020 – present). Professor of Law and Stephen C. O’Connell Chair, Fredric G. Levin College of Law; Professor of Engineering, Herbert Wertheim College of Engineering. Classes Taught. Torts, Biotechnology & Medical AI, Health Law Survey Research interests. Legal and ethical issues with artificial intelligence/machine learning clinical decision support and diagnostic support software. Data privacy. Financing, governance, and access to data for large-scale medical data commons and the rights of people whose data are held in medical and genomic databases. Regulatory issues with novel gene-editing technologies and genomic and other diagnostic tests. Food & Drug Administration regulatory matters, especially for medical devices. Health care law. Publications. See pages 9 – 19 PRIOR EMPLOYMENT 2007 – 2020 University of Houston, Houston, TX University of Houston Law Center (2007-2020), Mary Ann and Lawrence E. Faust Professor of Law (2018-2020) and Director, Center for Biotechnology & Law (2007-2020), University of Houston Cullen College of Engineering (2017-2020), Professor of Electrical and Computer Engineering (2017-2020).
    [Show full text]
  • BIOGRAPHICAL SKETCH Ellen Wright Clayton, J.D., M.D. Professor
    BIOGRAPHICAL SKETCH Provide the following information for the key personnel and other significant contributors in the order listed on Form Page 2. Follow this format for each person. DO NOT EXCEED FOUR PAGES. NAME POSITION TITLE Ellen Wright Clayton, J.D., M.D. Professor of Pediatrics Professor of Law eRA COMMONS USER NAME Co-Director, Center for Biomedical Ethics and claytoew Society EDUCATION/TRAINING (Begin with baccalaureate or other initial professional education, such as nursing, and include postdoctoral training.) DEGREE INSTITUTION AND LOCATION YEAR(s) FIELD OF STUDY (if applicable) Duke University, Durham, North Carolina B.S. 1970-1974 Zoology Stanford University, Stanford, California M.S. 1974-1976 Biology Yale Law School, New Haven, Connecticut J.D. 1976-1979 Law Harvard Medical School, Boston, Massachusetts M.D. 1981-1985 Medicine A. Positions and Honors 1985 Visiting Assistant Professor (Spring Semester), Law School and Program in Medical Ethics, University of Wisconsin, Madison, WI 1985-1988 Resident, Department of Pediatrics, University of Wisconsin Hospital and Clinics, and Lecturer, Program in Medical Ethics, Madison, WI 1988-1996 Assistant Professor of Pediatrics, Vanderbilt University School of Medicine, Nashville, TN, Assistant Professor of Law, Vanderbilt University School of Law, Nashville, TN 1996-1999 Associate Professor of Pediatrics, Vanderbilt University School of Medicine, Nashville, TN 1996-1999 Associate Professor of Law, Vanderbilt University School of Law, Nashville, TN 1989-1995 Member, Committee on Bioethics, American Academy of Pediatrics 1995-1998 Member, National Advisory Council, National Human Genome Research Institute 1997-2000 Member, ELSI Research Program & Evaluation Group, Nat’l Human Genome Research Institute 1997-2001 Editor-in-Chief, Journal of Law, Medicine and Ethics 1999-Pres Professor of Pediatrics, Vanderbilt University School of Medicine, Nashville, TN 1999-Pres.
    [Show full text]
  • Biobanking, Bioethics & The
    Biobanking, Bioethics & The Law September 26th, 2008 Stanford Law School 9:15 Welcome and Introduction 9:30 - 10:45 The Scientific Promise of Biobanks Russ Altman, Professor of Bioengineering, Genetics, and Medicine; Director, Biomedical Informatics Training Program, Stanford University Rex Chisholm, Adam and Richard T. Lind Professor of Medical Genetics; Dean for Research, Feinberg School of Medicine, Northwestern University Douglas Levinson, Walter E. Nichols, M.D. Professor in the School of Medicine, Stanford University Scott VandenBerg, Professor of Pathology and Neurosurgery; Director, Brain Tumor Research Center Tissue Core; Director, Neuropathology Biomarkers Laboratory, University of California San Francisco 10:45 - 11:00 Coffee Break 11:00 - 1:00 The Administration of Biobanks and Review of Research Mariana Bledsoe, National Institute of Health Elena Grigorenko, Child Study Center; Department of Psychology; Department of Epidemiology & Public Health, Yale University Julie Kaneshiro, Policy Team Leader, Office for Human Research Protections Elizabeth Peloso, Director of Compliance; Adjunct Professor of Psychology, University of Delaware Susan Stayn, Senior University Counsel, Office of General Counsel, Stanford University 1:00 – 1:30 Break 1:30 - 2:30 Lunch and Keynote Address: Hakon Hakonarson, Director, Center for Applied Genomics, The Children’s’ Hospital of Philadelphia; Associate Professor, Department of Pediatrics, University of Pennsylvania School of Medicine 2:30 - 4:00 Legal and Ethical Issues Related to Biobanks Kelly
    [Show full text]
  • The Magazine of Vanderbilt University's College of Arts And
    artsandS CIENCE The magazine of Vanderbilt University’s College of Arts and Science SPRING 2009 spring2008 artsANDSCIENCE 1 whereAER YOU? DANIEL DUBOIS Answer found on the back cover tableOFN CONTE TS SRN P I G 2009 20 12 6 30 6 Stay, Root and Invest departments Carolyn Dever, the new dean of the College of Arts and Science, A View from Kirkland Hall 2 embraces opportunities and relationships. Arts and Science Notebook 3 Open Book 5 8 2 1 Arts and Science in the World Beyond a Rock and a Frozen Place Five Minutes With… 10 Molly Miller makes Earth science come alive, even in the coldest spot on the planet. Up Close 14 Great Minds 16 0 2 The Convergence of Arts and Science Rigor and Relevance 18 And the Award Goes To 26 When the natural sciences, humanities and social sciences intersect, Forum 28 the road leads to learning, creativity and original thought. First Person 30 Giving 32 artsANDSCIENCE© is published by the College of Arts and Science at Vanderbilt University Back in the Day 34 in cooperation with the Office of Development and Alumni Relations Communications. You In Place 36 may contact the editor by e-mail at [email protected] or by U.S. mail 38 at PMB 407703, 2301 Vanderbilt Place, Nashville, TN 37240-7703. Parting Shot Editorial offices are located in the Loews Vanderbilt Office Complex, 2100 West End Ave., Suite 820, Nashville, TN 37203. Nancy Wise, EDITOR Donna Pritchett, ART DIRECTOR Jenni Ohnstad, DESIGNER Neil Brake, Daniel Dubois, Steve Green, Jenny Mandeville, John Russell, PHOTOGRAPHY Carolyn Dever, DEAN Jonathan S.
    [Show full text]
  • Ellen Wright Clayton Era COMMONS USER NAME
    Contact PD/PI: Clayton, Ellen W BIOGRAPHICAL SKETCH Provide the following information for the Senior/key personnel and other significant contributors. Follow this format for each person. DO NOT EXCEED FIVE PAGES. NAME: Ellen Wright Clayton eRA COMMONS USER NAME (credential, e.g., agency login):claytoew POSITION TITLE: Craig-Weaver Chair and Professor of Pediatrics, Professor of Law, Co-Founder, Center for Biomedical Ethics and Society EDUCATION/TRAINING (Begin with baccalaureate or other initial professional education, such as nursing, include postdoctoral training and residency training if applicable. Add/delete rows as necessary.) DEGREE Completion (if Date FIELD OF STUDY INSTITUTION AND LOCATION applicable) MM/YYYY Duke University, Durham, North Carolina BS 05/1974 Zoology Stanford University, Stanford, California MS 06/1976 Biology Yale Law School, New Haven, Connecticut JD 05/1979 Law Harvard Medical School, Boston, Massachusetts MD 05/1985 Medicine A. Personal Statement My work focuses on the appropriate conduct of genomics research, addressing issues ranging from the roles of consent and governance, and the implementation of its fruits into clinical care, including developing criteria and defining the roles of various decision makers, including patients, physicians, family members, professional organizations, and regulators. I use a variety of methodologies in these studies: legal analysis, normative ethical analysis, and qualitative and quantitative research assessing the views of patients, and research participants, most recently regarding pharmacogenomic testing and in the eMERGE consortium’s large population-based survey of opinions about broad consent for research use and data sharing. I have had the opportunity to address many of these critical policy issues in real time, having served as Co-Chair of the ELSI Working Group of the International HapMap Project, as well as playing a leadership role in developing and guiding Vanderbilt’s innovative BioVU resource.
    [Show full text]
  • Development of an Early Identification and Response Model of Malpractice Prevention
    HICKSON.FMT 04/01/98 8:07 AM DEVELOPMENT OF AN EARLY IDENTIFICATION AND RESPONSE MODEL OF MALPRACTICE PREVENTION * ** *** GERALD B. HICKSON, JAMES W. PICHERT, CHARLES F. FEDERSPIEL, **** AND ELLEN WRIGHT CLAYTON I INTRODUCTION The dramatic rise in the incidence of malpractice claims over the past thirty years has revealed several problems with the U.S. system of medical dispute resolution. First, the sudden and unexpected increase in claims has created an insurance crisis wherein various medical specialists have had difficulty obtain- ing affordable insurance coverage.1 One such crisis occurred in Florida in the mid-1980’s, when an inability of many physicians to procure medical malprac- tice coverage caused some to limit or curtail their practice. This resulted in ac- cess problems for the public. This phenomenon has disproportionately befallen physicians practicing obstetric medicine.2 Second, besides contributing to peri- odic crises of access, the current medical dispute resolution system is often re- sponsible for long delays in resolving claims and in compensating victims.3 Copyright © 1997 by Law and Contemporary Problems * Department of Pediatrics and Office of Insurance and Risk Management, Vanderbilt Univer- sity Medical Center. ** Department of Medicine and Office of Insurance and Risk Management, Vanderbilt Univer- sity Medical Center. *** Department of Preventive Medicine, Vanderbilt University Medical Center. **** Department of Pediatrics, Vanderbilt University Medical Center; School of Law, Vanderbilt University. This paper was supported in part by the Robert Wood Johnson Foundation, Grant No. 028592 (MMC), and by the Office of Risk Management of Vanderbilt University. The authors thank Cynthia S. Miller, MSW, for assistance on this project and Alma Catlin for clerical support.
    [Show full text]
  • Joint Proclamation by the Heads of Government of Six Countries Regarding the Completion of the Human Genome Sequence
    Joint Proclamation by the Heads of Government of Six Countries Regarding the Completion of the Human Genome Sequence We, the Heads of Government of the United States of America, the United Kingdom, Japan, France, Germany, and China, are proud to announce that scientists from our six countries have completed the essential sequence of three billion base pairs of DNA of the human genome, the molecular instruction book of human life. Remarkable advances in genetic science and technology have been made in the five decades since the landmark discovery of the double-helix structure of DNA in April 1953. Now, in the very month and year of the 50th anniversary of that important discovery by Watson and Crick, the International Human Genome Sequencing Consortium has completed decoding all the chapters of the instruction book of human life. This information is now freely available to the world without constraints via public databases on the World Wide Web. This genetic sequence provides us with the fundamental platform for understanding ourselves, from which revolutionary progress will be made in biomedical sciences and in the health and welfare of humankind. Thus, we take today an important step toward establishing a healthier future for all the peoples of the globe, for whom the human genome serves as a common inheritance. We congratulate all the people who participated in this project on their creativity and dedication. Their outstanding work will be noted in the history of science and technology, and as well in the history of humankind, as a landmark achievement. We encourage the world to celebrate the scientific achievement of completing the Human Genome Project, and we exhort the scientific and medical communities to rededicate themselves to the utilization of these new discoveries to reduce human suffering.
    [Show full text]
  • Biomedical Ethics in US Public Policy
    Appendix C Acknowledgments OTA thanks the many individuals and organizations that generously supplied information for this study. In addition, OTA acknowledges the following individuals for their review of drafts of this background paper: J.G.M Aartsen S.R. Benatar Health Council of the Netherlands University of Cape Town The Hague, The Netherlands Cape Town, South Africa Duane F. Alexander Bela Blasszauer National Institute of Child Health Medical University of Pees and Human Development Pecs, Hungary Bethesda, MD Dan W. Brock Margaret A. Anderson Brown University American Public Health Association Providence, RI Washington, DC Christian Byk Paul W. Armstrong Paris, France Bridgewater, NJ Daniel Callahan Christian Bardoux The Hastings Center Commission of the European Communities Briarcliff Manor, NY Brussels, Belgium Alastair V. Campbell Nora K. Bell University of Otago University of South Carolina Dunedin, New Zealand Columbia, SC 84 Appendix C-Acknowledgments I 85 Arthur L. Caplan John 1, Fleming University of Minnesota Southern Cross Bioethics Institute Minneapolis, MN Plympton, Australia Peter Carpenter John C. Fletcher Stanford University University of Virginia Atherton, CA Charlottesville, VA Max Charlesworth S.S. Fluss North Carlton, Australia World Health Organization Geneva, Switzerland R. Alta Charo University of Wisconsin Law School Patricia Anne Flynn Madison, WI St. Mary’s College of California Moraga, CA James Childress Heman L. Fuenzalida University of Virginia Pan American Health Organization Charlottesville, VA Washington, DC Ellen Wright Clayton K.W.M. Fulford The Vanderbilt Clinic University of Oxford Nashville, TN Oxford, United Kingdom Robert M. Cook-Deegan Bradford H. Gray Institute of Medicine Yale University Washington, DC New Haven, CI’ Jean Davies Jiri F.
    [Show full text]
  • TRANSCRIPT Current Issues in Genetics
    TRANSCRIPT Current Issues in Genetics Ellen Wright Clayton, J.D., M.D. Craig-Weaver Professor of Pediatrics; Professor of Law; Director, Center for Biomedical Ethics and Society; Vanderbilt University Susan Wolf, J.D. McKnight Presidential Professor of Law, Medicine & Public Policy; Faegre & Benson Professor of Law; Professor of Medicine; Faculty Member, Center for Bioethics; University of Minnesota Erik Parens, Ph.D. Senior Research Scholar, The Hastings Center Meeting 4, Session 4 February 28, 2011 Washington, D.C. DR. WAGNER: Okay, since our other Commissioners have the privilege of having your bios in their briefings, I’ll go ahead and introduce you to the rest of the room. We welcome today, Ellen Clayton, who is the Craig-Weaver Professor of Pediatrics and Professor of Law at Vanderbilt. She has advised the National Institutes of Health and other Federal and international bodies on topics ranging from children’s health to the ethical conduct of research. She received the William G. Bartholomew Award for Ethical Excellence from the American Academy of Pediatrics Section of Bioethics, and maybe the thing to do, a few of us have already spun up, Ellen, rather than introduce all three of you, I’ll let Ellen go ahead and make her presentation. DR. CLAYTON: Well, let me begin first by thanking you for inviting me to make a presentation to you. I want to make three quick comments, in response to Hank, and then I’m going to proceed to the purpose of my talk. With regard to his final comments about data, I would suggest that there are three major problems.
    [Show full text]
  • Ellen Wright Clayton CURRICULUM VITAE February, 2020 Name
    Ellen Wright Clayton CURRICULUM VITAE February, 2020 Name: Ellen Wright Clayton Addresses: Center for Biomedical Ethics and Society 2525 West End Ave., Suite 400 Nashville, TN 37203 (615) 322-1186 Vanderbilt University School of Law Nashville, TN 37240 (615) 322-1186 E-mail: ELLEN. [email protected] Date of Birth: June 22, 1952 Place of Birth : Houston, TX Home Address : 504 Fairfax Avenue Nashville, TN 37212 (615) 385-3779 Education: 1970-74: B.S., Duke University, Zoology 1974-76: M.S., Stanford University, Biology 1976-79: J.D., Yale Law School 1981-85: M.D., Harvard Medical School Postgraduate Training: 1985-88: Resident, Department of Pediatrics, University of Wisconsin Hospital and Clinics, and Lecturer, Program in Medical Ethics Licensure and Certification: 1988- : License to Practice Medicine, Tennessee #MD0000018825 1989- : Certification, American Board of Pediatrics #211033 1991- : Fellow, American Academy of Pediatrics #140172001 1988- : Inactive Member, State Bar of Texas Academic Appointments: Ellen Wright Clayton 1982-83: Research Assistant, Professor Jay Katz, Yale University, worked on his book, The Silent World of Doctor and Patient, Free Press, 1985 1985: Visiting Assistant Professor (Spring Semester), Law School and Program in Medical Ethics, University of Wisconsin 1988-96: Assistant Professor of Pediatrics, Vanderbilt University Medical School Assistant Professor of Law, Vanderbilt University School of Law Fellow, Vanderbilt Institute for Public Policy Studies, Center for Health Policy 1993: Visiting Professor of Law, University of Houston Law Center, Health Law and Policy Institute 1996-99: Associate Professor of Pediatrics with tenure, Vanderbilt University Medical School Associate Professor of Law, Vanderbilt University School of Law Faculty Member, Vanderbilt Program in Human Genetics Senior Fellow, Vanderbilt Institute for Public Policy Studies, Center for Health Policy Associate, Center for Clinical and Research Ethics 1999-05: Director, Center for Genetics and Health Policy 1999-2010: Rosalind E.
    [Show full text]